Last updated on August 2017

Study to Assess the Safety Pharmacokinetics and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke


Brief description of study

This is a Phase 1b/2, double-blind (Principal Investigators and study subjects blinded, Sponsor unblinded), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DS-1040b in subjects with Acute Ischemic Stroke (AIS).

Clinical Study Identifier: NCT02586233

Contact Investigators or Research Sites near you

Start Over

INC Research

Klinikum Altenburger Land
Altenburg, Germany
7.22miles
  Connect »